GlassScriptPhysician profile
Walter Mullins
NPI 1730154808
$4,962.86
in general payments reported to CMS, 2019-2025
33 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $325 · 2021: $464 · 2022: $773 · 2023: $608 · 2024: $1,072 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,100.76 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $523.16 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $482.39 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $475.57 | 2019-2025 | Stelara, Simponi Aria, Tremfya |
| Ardelyx, INC. | $338.90 | 2022-2025 | Ibsrela |
| Micro-Tech Endoscopy USA, INC. | $309.63 | 2021-2024 | |
| Genzyme Corporation | $254.14 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $227.74 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $212.65 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $190.79 | 2019-2024 | Rebyota |
| Madrigal Pharmaceuticals | $135.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $98.92 | 2024-2025 | Dupixent |
| Daiichi Sankyo INC. | $83.62 | 2020-2022 | |
| Pharmacosmos Therapeutics INC. | $62.70 | 2021-2023 | Monoferric |
| Intercept Pharmaceuticals, INC. | $53.61 | 2020-2023 | Ocaliva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $51.05 | 2024-2025 | Vegzelma |
| Allergan, INC. | $45.79 | 2019 | |
| Phathom Pharmaceuticals, INC. | $45.04 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $44.17 | 2022 | |
| Ironwood Pharmaceuticals, INC | $32.57 | 2020-2024 | |
| Gilead Sciences, INC. | $25.62 | 2019-2025 | |
| Qol Medical, LLC | $22.67 | 2022 | |
| Olympus America INC. | $19.83 | 2019 | |
| Shionogi INC | $16.80 | 2019 | |
| Braintree Laboratories, INC. | $15.44 | 2024 | Sutab, Suflave |
| Evoke Pharma, INC. | $15.40 | 2022 | |
| Novo Nordisk INC | $14.70 | 2025 | Wegovy |
| Apollo Endosurgery US INC | $13.83 | 2019 | |
| Ucb, INC. | $13.75 | 2019 | |
| Boston Scientific Corporation | $12.42 | 2022 | |
| Mallinckrodt Hospital Products INC. | $12.12 | 2022 | |
| Merck Sharp & Dohme LLC | $12.05 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$59,349.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.